Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis
Andrew Kuykendall, Nathan P. Horvat, Garima Pandey, et al.
Cancers (2020) Vol. 12, Iss. 8, pp. 2278-2278
Open Access | Times Cited: 18

Showing 18 citing articles:

Momelotinib: an emerging treatment for myelofibrosis patients with anemia
Helen T. Chifotides, Prithviraj Bose, Srđan Verstovšek
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 63
JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation
Garima Pandey, Andrew Kuykendall, Gary W. Reuther
Blood Cancer Journal (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 24
Targeted Therapies in Cancer: To Be or Not to Be, Selective
Skye Montoya, Deborah Soong, Nina Nguyen, et al.
Biomedicines (2021) Vol. 9, Iss. 11, pp. 1591-1591
Open Access | Times Cited: 31
JAK2 Alterations in Acute Lymphoblastic Leukemia: Molecular Insights for Superior Precision Medicine Strategies
Charlotte E. J. Downes, Barbara J. McClure, Daniel P. McDougal, et al.
Frontiers in Cell and Developmental Biology (2022) Vol. 10
Open Access | Times Cited: 20
Disease Modification in Myelofibrosis: An Elusive Goal?
Pankit Vachhani, Srđan Verstovšek, Prithviraj Bose
Journal of Clinical Oncology (2022) Vol. 40, Iss. 11, pp. 1147-1154
Open Access | Times Cited: 18
Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms
Prithviraj Bose, Lucia Masárová, Srđan Verstovšek
Cancers (2020) Vol. 12, Iss. 10, pp. 2891-2891
Open Access | Times Cited: 14
Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms
Yammy Yung, Emily Lee, Hiutung Chu, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 2, pp. 659-659
Open Access | Times Cited: 12
SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms
Garima Pandey, Lucia Mazzacurati, Tegan M. Rowsell, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 6, pp. 1040-1055
Open Access | Times Cited: 1
Molecular biomarkers of leukemia: convergence-based drug resistance mechanisms in chronic myeloid leukemia and myeloproliferative neoplasms
Meike Kaehler, Nikolas von Bubnoff, Ingolf Cascorbi, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Targeting Janus Kinase (JAK) for Fighting Diseases: The Research of JAK Inhibitor Drugs
Minyan Zhao, Wen Zhang, Guo‐Wu Rao
Current Medicinal Chemistry (2022) Vol. 29, Iss. 29, pp. 5010-5040
Closed Access | Times Cited: 7
Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms
Vasundhara Sharma, Kenneth L. Wright, Pearlie K. Epling‐Burnette, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 8
Synthesis and biological evaluation of novel 2,4-dianilinopyrimidine derivatives as potent dual janus kinase 2 and histone deacetylases inhibitors
Haiping Zhou, Junhao Jiang, Jinyu Lu, et al.
Journal of Molecular Structure (2021) Vol. 1253, pp. 132200-132200
Closed Access | Times Cited: 6
JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis
Andrew Kuykendall, Rami S. Komrokji
Journal of Immunotherapy and Precision Oncology (2021) Vol. 4, Iss. 3, pp. 129-141
Open Access | Times Cited: 4
PU-H71 (NSC 750424): a molecular masterpiece that targets HSP90 in cancer and beyond
Sameh Saber, Rasha Abdelhady, Mai A. Elhemely, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Degradation of Janus Kinase for Potential Application in Immune Response Therapeutics
Robert B. Kargbo
ACS Medicinal Chemistry Letters (2021) Vol. 12, Iss. 3, pp. 316-317
Open Access | Times Cited: 3
The Role of Navitoclax in Myelofibrosis
Sasirekha Pandravada, Steven Sandler
Cureus (2021)
Open Access | Times Cited: 1
Logical modelling of myelofibrotic microenvironment predicts dysregulated progenitor stem cell crosstalk
Stephen P. Chapman, Estelle Duprez, Élisabeth Rémy
Biosystems (2023) Vol. 231, pp. 104961-104961
Open Access
Logical modelling of myelofibrotic microenvironment predicts dysregulated progenitor stem cell crosstalk
Stephen P. Chapman, Estelle Duprez, Élisabeth Rémy
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access
Page 1

Scroll to top